Trial Profile

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rucaparib (Primary)
Indications Adenocarcinoma; Carcinoma; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms TRITON2
Sponsors Clovis Oncology [CEASED]; pharmaand GmbH

Most Recent Events

08 Mar 2024 This trial has been competed in Italy, according to European Clinical Trials Database record.
15 Aug 2023 Final results from the Phase 2 TRITON2 Study published in the European Urology
01 Mar 2023 Results (n=100) assessing the prevalence of BRCA reversion mutations in the plasma of patients with BRCA+ mCRPC after progression on rucaparib published in the European Urology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com